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CHAPTER SIXTEEN

Division of Medical
Oncology
WILLIAM

E.

DELANEY, M.D.

"While there are several chronic diseases
more destructive to life than cancer)
H.
(1865-1939)
none is more [eared.J)
-CHARLES

LTHOUGH medical oncology was first
officially recognized as a medical
subspecialty by the American Board of
Internal Medicine in 1972, a formal Division of
Medical Oncology in the Department of Medicine
at Jefferson had been established since 1961. The
first Director (1961-1970) was Arthur Weiss, M.D.
(Figure T6-1), and the second (1970-1980) was
Chester Southam, M.D. (Figure J6-2). Acting
Directors were William E. Delaney, M.D.
(Jefferson, 1953; 1980-1981) and J. Frederick
Laucius, M.D. (Jefferson, 1967; 1981-19R4). The
third Director is Michael J. Mastrangelo, M.D.,
appointed in 1984.
The major activities of the Division since its
inception have been patient care, teaching,
research, and the training of medical oncology
Fellows. Among the latter, the first Fellows were
Laird Jackson, M.D., who was the first National
Institutes of Health Postdoctoral FelJow (19611962), and Harvey Brodovsky, M.D. (1961-1963).
Several additional Fellows have served in the
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Division since that time, most notably Carla
Goepp, M.D. (hgure 16-3), (1965-1967), who
became Associate Dean of Student Affairs and
Director of the Office of Student Counseling and
Career Planning, and Michael J. Mastrangelo,
M.D. (1968-1970). Significant accomplishments in
cancer care, research, and teaching at Jefferson
occurred in the years before the establishment of
the Division.

The Tumor Clinic and Elizabeth
Storck I(raemer Foundation
The Tumor Clinic was informally begun in 1928
and has continued since that date as the major
institutional follow-up mechanism for cancer
patients. Formal establishment began in the fall of
1929 when, through the auspices of William H.
Kraemer, M.D. (Figure 16-4, Jefferson, 1906),

:;62 • Thoma.f Jeffimon University

Associate Professor of Surgery, a grant received
from Mr. Pierre S. DuPont, consisting initially of
$35,000 plus $10,000 annually for five years, was
augmented by an initial grant of $15,000 for one
year from Mr. Lanunot DuPont. Through an
additional 30 years (]934-1964-), Pierre DuPont
provided the sole support of Jefferson's Tmuor
Clinic through annual grants from the Longwood
foundation to the Elizabeth Storck Kraemer
Foundation.
All of the Department Chairmen have served as
Attending Physicians or Surgeons in the Tmnor
Clinic. Outstanding contributors to the activity of
the Tumor Clinic over the years have been Drs.
James M. Surver (Assistant Professor of Surgery),
Harry]. Knowles (Assistant Professor of Surgery),

and Gerald J. Marks (Professor of Surgery), who
directed the day-to-day activities of the staff.
The Tumor Registry began as an offshoot of the
Tmnor Clinic in June, 1959. From that time
through December 1983, as many as 28,593 patients
have been accessioned, and 19,139 patients are
known to have died. By June 1984-, as many as
9,973 patients were under active follow-up, a rate
of 92.3 percent. This Registry is the resource for
all professionals interested in follow-up data over
the years for Jefferson's oncology activities. Its
overall direction is through the Cancer Committee
of the Hospital.
The other major activity of the Elizabeth Storck
Kraemer Foundation was to provide an
investigative arm for the development of new
cancer treatment drugs that had been isolated or
synthesized by chemists of the DuPont Company.
Dr. Kraemer died in March, 1962, and on
December 31, 1964-, the Foundation was dissolved.
For nearly 35 years it had actively supported not
only the Tmnor Clinic and weekly Tmnor Clinic
conferences but also chemical research at the
DuPont experimental station in Wilmington,

FIG. ]6-1. Arthur Weiss, M.D.; First Director, Division of
Oncology (1961-1970).

FIG. 16-2. Chester Southam, M.D.; Director, Division of
Oncology (1970- 1980).
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Delaware, ,md biological research conducted
by the Department of Pathology under the
supervision of Dr. Peter A. Herbut. Dr. Herbut
was Director of the Biological Division of the
Fow1dation, incorporated from September, 194-6,
to December 31, 1964-, on a stipend of $200 a
month payable by the Tumor Clinic. Dr Kraemer
was Director of Research from 1929 until his
death. The funding after 1964- came through the
Hospital budget.
The first publication from the Foundation
appeared in 1931 and was a preliminary report on
colloidal lead phosphate with manganese as an
anticarcinogenic agent. 2 In subsequent years the
Foundation was responsible for 22 publications in
experimental cancer by Dr. Herbut, 14- of which
were coauthored with Dr. Kraemer. In a 1955
article,3 Herbut and Kraemer stated that the
Walker Rat Mammary Carcinoma 256 had been
carried in their laboratory since 1936. Dr.
Kraemer's cancer research was recognized formally
by his Jefferson alma mater in the award of an
Honorary Degree of Doctor of Science at
graduation on June 16, 1961.

FIG. 16-3.

Carla Goepp, M.D.

William H. Kraemer (born 1879) came to the
United States as a boy from Germany. The family
settled in West Virginia where he learned frugality
and a proper set of values. He was trained as a
pharmacist, and his application to Jefferson was
accepted on the basis of his pharmacy credits. He
worked at pharmacies during medical school and
graduated in 1906. While working as a physician
with the DuPont Company, he began to
experiment on cancer in his garage using rats he
caught there.
In 1926 Dr. Kraemer attracted the attention of
Pierre S. DuPont, who requested his treatment for
a leg ulcer that DuPont attributed to a kick by
John J. Raskob intended to keep him awake
during a General Motors Corporation board
meeting. Dr. Kraemer had x-rays talcen of Du
Pont's teeth out of desperation because he had

FIG. [6-4.

William H. Kraemer, M.D.
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found nothing systemically to account for the
poor healing. The film revealed two abscessed
wisdom teeth on each side, which Kraemer
believed to have contributed to DuPont's
somnolence. He immediately brought his patient
to Jefferson, and taking a hospital room next to
DuPont for himself, began to take care of all his
health needs, including extraction of the teeth.
Although the mandible was fractured in the
extraction of the teeth, rendering DuPont
speechless for a time, DuPont was grateful because
his somnolence completely disappeared. While
recuperating, DuPont communicated with Dr.
Kraemer by written notes. In one of them he
asked: "What is this I hear about your
experimenting with cancer in the garage?" Dr.
Kraemer told him about it and suggested that
DuPont Company's vast chemical expertise be
used to develop cancer chemotherapy.
In addition to personal physician, Dr. Kraemer
became a friend and confidant. He played golf
with DuPont, went on trips with him, and with
Mrs. Kraemer moved to the DuPont area. Mr
DuPont put him on a lifetime retainer of $6,000
per year and gave Mrs. Kraemer $5,000 per year
for life. He also set up the Elizabeth Storck
Kraemer Memorial Foundation in honor of Dr.
Kraemer's second wife, who died of cancer.
In the early years, the biological aspect was
carried out in New York's Memorial Hospital for
Cancer, through Dr. James Ewing and later at
New York University by Dr. Robert Chambers. In
the mid-1940S, following Dr. Chamber's death,
biological studies were centered at Jefferson. The
chemical division of the Elizabeth Storck Kraemer
Memorial Foundation was headquartered in the
experimental station in Wilmington, Delaware.
Toward the end, the annual budget of the
Foundation should be funded for ten years after
his death or until Dr. Kraemer died, whichever
was longer. Pierre DuPont died in 1954. William
H. Kraemer died March 20, 1962, and the
Foundation was dissolved December 31, 1964. The
Directors in 1964 are listed in Volume 2 of the
Herbut Papers in the Scott Library's Special
Collections. The Foundation was headquartered in

room 2095, DuPont Building, Wilmington,
Delaware. By December 3, 1959, the Foundation
had completed its thirty-first year of activity, and
during that time 4,000 chemicals had been
screened for antitumor activity and 1,000 cancer
patients had received chemotherapy. Mter the 1964
termination of the research support, the Trustees
of the Foundation granted $24,650 to Jefferson
Medical College for research at Dr. Herbut's
discretion. As an outgrowth of the research
activities that had been supported by the Kraemer
Foundation, a National Institutes of Health grant
award to Dr. Herbut was renewed for three years
in 1965.

The Interdepartmental Endocrine
and Cancer Research Group
The relationship between Drs. Abrahanl Cantarow
(Biochemistry), Karl E. Paschkis (Medicine)
(Figure 16-5), and Abraham E. Rakoff (Obstetrics
and Gynecology) led to their formation of an
informal endocrine and cancer research group in
1940. In 1945, at the close of World War II, they
began to contribute significantly to the literature,
and by 1959 they had realized more than 300
publications. The Board of Trustees in 1948
formally organized the Endocrine and Cancer
Research Group with Dr. Paschkis as the first and
only Director. He was the unique catalyst who
was involved in all activities of the group. It
received partial funding by the American Cancer
Society on the recommendation of the Committee
on Growth of the National Research Council and
by the National Cancer Institute.
In the field of steroid hormone metabolism they
originated the concept of the biliary excretion and
enterohepatic circulation of estrogens and
androgens. 4 They first showed that androgens
accelerated the development of malignant
hepatomas when the carcinogen 2-acetyl-aminofluorine (AAF) was fed to rats and that thiouracil
given with this chemical protected the liver
exposed to testosterone; in addition, they first
demonstrated the enhancement of the carcinogenic
action of progesterone on the breasts of rats
treated with AAF.5 Their work on pyrimidine
metabolism as related to normal growth of
malignant tumors led to the synthesis by Charles
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Heidelberg, Ph.D., at the University of Wisconsin,
of 5-fluorouracil, a drug widely used in many
cancer chemotherapy programs. 6 Their research
further indicated that in the presence of
regenerating liver, not only tumor growth but also
a large variety of nonmalignant growth proce:scs
were stimulated; similar effects could be obtamed
by injection of certain liver fractions.? Another
basic investigation was the transmission of tumor
by subcellular units. Thus, injection of isolated
tumor chromatin induced tumor growth m
recipient animals. The effect was noted to be
specific in that chromatin from malignant
lymphoma cells induced malignant lymp~oma
after subcutaneous injection and chromatm
from hepatoma cells induced hepatomas after
intrahepatic injection. 8- 1O
Dr. Paschkis faced his own terminal illness from
bronchogenic carcinoma with composed heroism.
With his death of January 27, 1961, at age 65, the
Endocrine and Cancer Research Group ceased to
function as a unit and was dissolved.

Cooperative Cancer Therapy
Groups
Among the earliest investigators cooperating with
other institutions in the evaluation of new drugs
tor the management of cancer, Arthur Weiss,
M.D., Assistant Professor of Medicine, was the
leader at Jefferson since 1958, when he established
the Jefferson branch of the Clinical Drug
Evaluation Program of the Cancer Chemotherapy
National Service Center, a subsidiary of the
National Cancer Institute. In 1960, Dr. Weiss also
led Jefferson into the Central Oncology Group as
a cochairman of that body. In addition, in 1960,
Farid Haurani, M.D., became the representative at
Jefferson of the Cancer and Acute Leu.kemia
Group B in an association that lasted through
1981. Eastern Cooperative Oncology Group
participation has been continuous since 1968 at
Jefferson under the direction of Harvey
Brodovsky, M.D. He has been a coauthor of 17
papers published on EC?G trials and was a gr~nt
recipient of ECOG fundll1g for many years until
1981.
A significant contribution to the use of
adriamycin in chemotherapy occurred when the
Cooperative Group, wid1 Arthur WeISS, ~.D., as
d1e senior author and R. William MantheI, Ph.D.,
Professor of Pharmacology, as coauthor, reported
the decrease in cardiac toxicity of low-dose
infusions at frequent intervals as compared to the
significant cardiac toxicity of high-dose bolus
therapy with this drug." This modified the
approach to the use of this excellent
.
chemotherapeutic agent and has extended Its
useful application in aU fields of cancer
chemotherapy.

Applied Research and Clinical
Oncology
FIG. [6-5. Karl Paschkis, M.D.

Shortly after exfoliative cytology was .develop~d in
the early 194-0S by Dr. George PapanIColaou, Its
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application to the detection and eradication of
gynecologic tumors was led by such men at
Jefferson as Lewis C. Scheffey (Jefferson, 1920),
Professor of Gynecology, and Abraham E. Rakoff
(Jefferson, 1937), Professor of Gynecologic and
Obstetrical Endocrinology.
The bronchoscopic diagnosis in lung cancer by
cytology studies of aspirated secretions won for
Louis H. Clerf (Jefferson, 1912), Chairman of the
Department of Otolaryngology, and Peter A.
Herbut, Chairman of the Department of
Pathology, the Gold Medal of the American
Medical Association in 195I.
Early research into naturally occurring
stimulators and inhibitors of granulocytic and
lymphocytic proliferation in human leukemia was
the special interest of Franklin Miller, M.D.,
Assistant Professor of Medicine, who was one of
the early associate members of the Cardeza
Foundation for Hematologic Research.
In the management of human breast cancer in
the 1950S, when endocrine manipulation of the
tumor was the major therapeutic modality, Ralph
A. Carabasi (J efferson, 194-6) was a pioneer. Early
immunologic studies in cancer were conducted by
Irwin L. Stoloff (Jefferson, 1951), in addition to
those performed by Chester Southam, M.D.
Lymphangiography was originally described as a
unilateral procedure for the analysis of lymph flow
in 1955. In 1960, Dr. Phillip Hodes, Professor and
Chairman of Radiology, and Dr. Simon Kramer,
Head of Radiation Therapy, realized that this
technique might be adaptable to the evaluation of
lymph node involvement by cancer. They
encouraged Sidney Wallace, M.D., Assistant
Professor of Radiology, and Laird Jackson, M.D.,
who was then a medical resident, to develop the
procedure. Drs. Wallace and Jackson performed
the first bilateral simultaneous injection of
intralymphatic contrast materials in humans in
1960. This was a tedious procedure in the
beginning, requiring prolonged hand-delivered
injections by two people, until Dr. Jackson
invented a motor-driven pump that became
universally used for lymphangiography. By 1985 the
information gained by lymphangiography was

largely replaced by noninvasive methods.
Laird G. Jackson, M.D., Professor of Pediatrics,
Director of the Division of Genetics, Professor of
Medicine and Professor of Obstetrics and
Gynecology, performed all of his early work in
chromosomes and on the genetics of cancer while
assigned to the Division of Medical Oncology of
the Department of Medicine. This began in 1961
when he was a medical oncology Fellow and
investigated chromosomes in leukemia. He
expanded this work after he took the Bar Harbor
course in medical genetics given by Victor
McCusick, M.D., in 1962.
With the return of Michael J. Mastrangelo,
M.D. (Figure 16-6) to Jefferson in 1984- to renew
an association he had begun as a medical intern in
1964-, Jefferson entered a new era of research and
therapy of malignant melanomas. Dr.
Mastrangelo's interest has been in the
immunologic aspects of cancers in general and of
malignant melanoma in particular since he took
postdoctoral training in the laboratory of
Richmond T. Prehn, M.D., in the Institute for
Cancer Research of Philadelphia (1971-1972).
Mastrangelo was an early member of the
Malignant Melanoma Clinical Cooperative Group
(1973-1977) and a member of the Committee on
Tumor Immunotherapy of the Division of Cancer
Biology and Diagnosis of the National Cancer

Michael J. Mastrangelo, M.D.; Director,
Division of Oncology (1984-).

FIG. 16-6.
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Institute (1975-1979). Since 1980 he has been a
member of the Experimental Therapeutic Study
Section of the National Institutes of Health,
serving from 1982 to 1984 as its Chairman. He
continues an active program in immunologic
aspects of cancer and of malignant melanoma in
particular.
Medical science is still at the frontier in
understanding the complex mechanisms that lead
to cancer, its better palliation, and the ultimate
goal of total prevention and cure. The progress
thus far engendered by interdepartmental
cooperation has been significant, but more intense
focus on the possible role of viruses not yet
isolated, genetic investigation, and study of
neoplasms at the molecular level will increase
Jefferson's stature in this field.
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